SUNNYVALE, Calif.--(BUSINESS WIRE)--Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease–modifying therapeutic protein, today provided shareholders with an update on the execution of its expanded corporate strategy, first announced on November 1st, 2011, to position Amarantus as a neurology-focused biotechnology company. Since that time, the Company has:
•Received grant funding for a Traumatic Brain Injury collaboration with Banyan Biomarkers from Brewer Sports International
